Skip to main content
. Author manuscript; available in PMC: 2016 Aug 17.
Published in final edited form as: J Cell Physiol. 2015 Oct;230(10):2447–2460. doi: 10.1002/jcp.24975

Fig. 10.

Fig. 10

Dose-dependence of BCI-121 treatment in CRC cell lines. (A) BCI-121 treatment for 48 h induces a concentration-dependent reduction of CRC cell proliferation and (B) decreases the global levels of targeted histone methyl marks [H4K5me, H3K4me2] and ERK 1/2 activation. A non-targeted methyl mark [H3K27me3] was not affected. β-actin was used as a loading control for immunoblotting. (C) The dose-dependent effect of BCI-121 treatment (72 h) on cell growth is observed in cells expressing high levels of SMYD3 (HCT116), but not in cells with low levels of SMYD3 (LS174T). Cell proliferation was calculated using the WST-1 assay. Statistical analysis was performed using Student’s t-tail test; *P < 0.05, **P < 0.01, and ***P < 0.001 were considered statistically significant.